Retatrutide (also referred to as LY3437943) is an advanced triple incretin receptor agonist currently under investigation in preclinical and clinical research settings. Unlike dual agonists, retatrutide simultaneously targets three key metabolic receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. This trimodal mechanism of action makes it a particularly compelling compound for researchers studying energy homeostasis, adipose tissue metabolism, and glycaemic regulation.
In research models, retatrutide has demonstrated pronounced effects on body weight reduction and lipid metabolism, with data suggesting superior efficacy compared to single or dual receptor agonists at equivalent doses. Its glucagon receptor activity is believed to contribute to increased energy expenditure and hepatic fat reduction, adding a distinct dimension to its metabolic profile.
Recommended storage is at -20°C, protected from light and moisture, with reconstituted solution stored at 4°C and used within 30 days.
Molecular Formula
C₁₉₄H₃₁₄N₅₀O₅₈
Molecular Weight
4373.9 g/mol
Purity
>98%
CAS Number
2381090-02-2
Form
Lyophilised Powder
Research Applications
Metabolic disorder research, Obesity and weight regulation studies, Glycaemic control investigation, Lipid metabolism research, Energy homeostasis modelling, Non-alcoholic fatty liver disease (NAFLD) research
For research purposes only. Not for human use.
Reviews
There are no reviews yet.